Tillkännagivande • Jan 08
BioCorRx Inc. Announces Board Changes, Effective January 1, 2026 BioCorRx Inc. announced that Louis Lucido has been appointed Chair of the Company’s Board of Directors, effective January 1, 2026. Mr. Lucido succeeded Kent Emry, who has served on BioCorRx’s Board of Directors since 2013 and will continue to serve as an independent director, ensuring continuity of leadership and governance. Mr. Lucido has been a member of the BioCorRx Board of Directors since 2019 and has played an instrumental role in the Company’s development and supporting operational leadership during a pivotal period for the Company as President since 2024. In addition, Mr. Lucido brings extensive board leadership experience, including service as Chair of the Board for other organizations, which positions him well to lead BioCorRx as it advances its strategic objectives. Tillkännagivande • Apr 04
BioCorRx Inc. Announces Board Resignations On March 29, 2024, Brady Granier submitted his letter of resignation from his position as a member of the board of directors (the “ Board”) of BioCorRx Inc. (the “ Company”), effective March 31, 2024 (the “ Granier Resignation”). Additionally, on March 29, 2024, Harsha Murthy submitted his letter of resignation from his position as a member of the Board of the Company, effective April 2, 2024 (the “ Murthy Resignation”). The Granier Resignation and Murthy Resignation did not arise as a result of any disagreement with the Company nor BioCorRx Pharmaceuticals, a subsidiary of the Company. Tillkännagivande • Feb 09
BioCorRx Pharmaceuticals Inc. Appoints Kate Devarney to the Board of Directors BioCorRx Inc. announced that its subsidiary BioCorRx Pharmaceuticals Inc., has appointed Kate Beebe DeVarney, Ph.D. to its Board of Directors. Dr. DeVarney spearheaded the development of Probuphine® (buprenorphine implant), the first six-month, subcutaneous implant approved in the United States, Canada, and Europe for the treatment of opioid use disorder. Dr. DeVarney is the President, Chief Operating Officer, and a Director of Titan Pharmaceuticals Inc. She was previously Titan’s Chief Scientific Officer and has been with the company since 2007. During her tenure with Titan, Dr. DeVarney has been awarded and served as the Principal Investigator on multiple research grants funded by the National Institute on Drug Abuse (NIDA), and currently serves as an advisor on the National Advisory Committee on Drug Abuse (NACDA). Before joining Titan, she served as Senior Medical Director at Corcept Therapeutics Inc. and as Senior Medical Director for Neurosciences within World Wide Human Health at Merck & Co. Dr. DeVarney also held positions within the neurosciences research, development, and medical affairs organizations of SmithKline Beecham and GlaxoSmithKline. Throughout her academic and industry careers, Dr. DeVarney's research has focused primarily on substance use disorders, neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease, mood and anxiety disorders as well as metabolic disorders and obesity. Her research has been published in peer-reviewed medical journals such as The American Journal of Psychiatry, Drug and Alcohol Dependence, The Journal of the American Medical Association, and Addiction. She has also presented extensively at the American Psychiatric Association, the American College of Neuropsychopharmacology, the American Society of Addiction Medicine, and the International Society of Addiction Medicine. Tillkännagivande • Jan 06
BioCorRx Inc. Announces President Changes On December 29, 2023, Brady Granier submitted his letter of resignation as President of BioCorRx Inc. effective January 31, 2024. Mr. Granier will continue to serve as a member of the Company’s board of directors. Mr. Granier's resignation did not arise as a result of any disagreement with the Company nor BioCorRx Pharmaceuticals. On January 5, 2024, in light of the Granier Resignation, the Board appointed Louis Lucido as Interim President of the Company, effective immediately through January 31, 2024, and transitioning to President on February 1, 2024. Mr. Lucido will remain a member of the Board. Mr. Lucido, 75, was formerly the Senior Advisor and Chief Operating Officer of DoubleLine Group, LP. He was one of the five founding partners of DoubleLine in December of 2009. He was previously at TCW as a Group Managing Director. Prior to joining TCW in 2001, Mr. Lucido was the Chief Investment Officer for Delphi Financial Group (“DFG”) and on several subsidiary Boards. Before DFG, he was the Chief Operating Officer, MD, and Secretary for Hyperion Capital Management & was also a member of the Resolution Trust Advisory Committee. From 2013-2018, he served as a member of the Board of Directors of CASA of Los Angeles and Chair. Current member of the board for National CASA since 2018. Formerly served on the Boards of Junior Achievement, Southern California, 826LA, and the Lupus Research Alliance (formerly the Alliance for Lupus Research). Mr. Lucido received his MBA in Management and Finance from New York University and was a member of the Dean’s Advisory Board of the N.Y.U. Stern School of Business. Mr. Lucido has been a Director of BioCorRx Inc. since March 1, 2019. Tillkännagivande • Aug 17
BioCorRx Inc. Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder BioCorRx Inc. announced its submission to the US Food and Drug Administration (FDA) of an expanded access program application for BICX104 (implantable naltrexone pellet) for the treatment of opioid use disorder (OUD) patients that meet program eligibility criteria. Expanded access (also known as “compassionate use”) is an FDA program that allows drug companies to provide access to an investigational medical product before full FDA approval to patients with a serious or immediately life-threatening disease or condition where standard treatment options have been exhausted or are not suitable. Data published on the FDA website indicates a 98.4% approval rate (62 out of 63) for expanded access applications submitted to the Center for Drug Evaluation and Research (CDER) for treatment protocols between 2018 and 2022. BICX104, which is being developed by BioCorRx Pharmaceuticals Inc., the Company’s controlled clinical-stage pharmaceutical subsidiary, is a biodegradable, long-acting subcutaneous pellet of naltrexone for the treatment of OUD being developed with the goal of improving patient compliance to naltrexone therapy compared to other marketed treatments. The BICX104 clinical study was a Phase I, open-label, single-center study in two parallel groups of randomized healthy volunteers to evaluate the PK and safety of BICX104 implantable subcutaneous naltrexone pellets and the marketed once-a-month intramuscular depot naltrexone injection, Vivitrol. Information about the study can also be found at www.clinicaltrials.gov under NCT number 04828694. BICX104 is being developed through a cooperative agreement with the NIDA, part of NIH, under award number UH3DA047925, funded by the Helping to End Addiction Long-term Initiative or NIH HEAL Initiative. This award is subject to the Cooperative Agreement Terms and Conditions of Award as set forth in RFA DA-19-002 entitled, Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional). The NIH Helping to End Addiction Long-term® Initiative or NIH HEAL Initiative®, is an aggressive, trans-NIH effort to speed scientific solutions to stem the national opioid public health crisis. Launched in April 2018, the initiative is focused on improving prevention and treatment strategies for opioid misuse and addiction and enhancing pain management. Tillkännagivande • Jan 24
BioCorRx Inc. Appoints Harsha Murthy as A Member of the Board of Directors On January 20, 2023, BioCorRx Inc. (the “Company”) appointed Harsha Murthy as a member of the Board of Directors (the “Board”) of the Company (the “Murthy Appointment”). The Company and Mr. Murthy entered in a Director Agreement, dated January 20, 2023 (the “Murthy Director Agreement”). Pursuant to the Murthy Director Agreement, Mr. Murthy shall make reasonable business efforts to attend all Board meetings, serve on appropriate subcommittees as reasonably requested by the Board, make himself available to the Company at mutually convenient times and places, attend external meetings and presentations, as appropriate and convenient, and perform such duties, services and responsibilities, and have the authority commensurate to such position. Mr. Murthy will receive a quarterly cash stipend of $15,000. For so long as Mr. Murthy serves as the chair of either the Audit Committee of the Board, the Compensation Committee of the Board or the Nominating Committee of the Board, the amount of such quarterly cash stipend may be increased from time to time. Mr. Murthy will also be issued, upon the last day of each fiscal quarter, commencing in the quarter in which he enters into the Murthy Director Agreement, provided he is a member of the Board as of such date, the number of shares of the Company’s common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. Tillkännagivande • Jan 20
BioCorRx Inc. Announces Completion of Treatment Phase of Study Subjects and Preliminary Safety Data from Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder, Which is Being Developed Under BioCorRx Pharmaceuticals, Inc BioCorRx Inc. announced an update from the Phase I clinical trial of BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD), which is being developed under BioCorRx Pharmaceuticals, Inc., the Company’s controlled clinical stage pharmaceutical company. BICX104 is a biodegradable, long-acting subcutaneous pellet of naltrexone for the treatment of OUD being developed with the goal of improving patient compliance to naltrexone therapy compared to other marketed pharmacotherapies. The BICX104 clinical study is a Phase I, open-label, single-center study in two parallel groups of randomized healthy volunteers to evaluate the pharmacokinetics (PK) and safety of BICX104 implantable subcutaneous naltrexone pellets and the marketed once-a-month intramuscular depot naltrexone injection, Vivitrol. BICX104 is being developed through a cooperative agreement with the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), under award number 3UH3DA047925-03S, funded by the Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative. This award is subject to the Cooperative Agreement Terms and Conditions of Award as set in RFA DA-19-002 entitled, Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional). Tillkännagivande • Oct 14
BioCorRx Inc. Completes Final Subject Enrollment in Phase I Clinical Trial of BICX104 BioCorRx Inc. announced that the last subject has been enrolled in the Phase I clinical trial of BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD), which is being developed under BioCorRx Pharmaceuticals Inc., the Company’s controlled clinical stage pharmaceutical company. The BICX104 clinical study is a Phase I, open-label, single-center study in two parallel groups of randomized healthy volunteers to evaluate the pharmacokinetics and safety of BICX104 implantable subcutaneous naltrexone pellets and the marketed once-a-month intramuscular depot naltrexone injection, Vivitrol. The study is led by Dr. Joel M. Neutel M.D., Director of Research at the Orange County Research Center (OCRC), located in Tustin, CA. Information about the study can also be found at www.clinicaltrials.gov under NCT number 04828694. BICX104 is being developed in collaboration with the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), under RFA DA-19-002, “Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional).” The Company has an active Investigational New Drug (IND) status, and the FDA has deemed the 505(b)(2) abbreviated pathway acceptable, as well the opportunity to seek eventual dual indication on the product for OUD and Alcohol Use Disorder (AUD). Tillkännagivande • Jul 01
BioCorRx Inc. Announces First Subject Dosed in Phase I Clinical Trial of Bicx104 BioCorRx Inc. announced that the first subject has been dosed in the Phase I clinical trial of BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder, which is being developed under BioCorRx Pharmaceuticals Inc., the Company’s controlled clinical stage pharmaceutical company. The BICX104 clinical study is a Phase I, open-label, single-center study in two parallel groups of randomized healthy volunteers to evaluate the pharmacokinetics and safety of BICX104 implantable subcutaneous naltrexone pellets and the marketed once-a-month intramuscular depot naltrexone injection. The study is led by Dr. Joel M. Neutel M.D., Director of Research at the Orange County Research Center, located in Tustin, CA. Interested participants can reach out directly to OCRC. BICX104 is being developed in collaboration with the National Institute on Drug Abuse, part of the National Institutes of Health, under RFA DA-19-002, Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional). The Company has an active Investigational New Drug status, and the FDA has deemed the 505(b)(2) abbreviated pathway acceptable, as well the opportunity to seek eventual dual indication on the product for OUD and Alcohol Use Disorder. Tillkännagivande • Sep 24
BioCorRx Files Patent Application with USPTO for Naltrexone Implant BioCorRx Inc. announced that it has filed a patent application with the U.S. Patent and Trademark Office (USPTO) for a biodegradable implant including naltrexone. Several of the claims in the application are intended to cover BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD), being developed under BioCorRx Pharmaceuticals Inc., the Company’s controlled R&D subsidiary. BioCorRx has received clearance from the FDA to proceed to human trials for BICX104 and expects to initiate the first-in-human clinical trial of the drug candidate as soon as scheduling permits. The project has been funded in large part by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), under award number UG3DA047925 and is a result of BioCorRx’s application under RFA DA-19-002, Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional). Tillkännagivande • May 11
BioCorRx Inc. Receives FDA Clearance of Investigational New Drug (IND) Application for BICX104, its Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder BioCorRx Inc. announced that the U.S. Food and Drug Administration (FDA) has given the Company clearance to proceed to human trials for BICX104, an implantable naltrexone pellet for the treatment of Opioid Use Disorder (OUD). The company submitted the IND to the FDA last month. The first-in-human clinical trial for BICX104 is expected to commence later this year. BICX104 is a biodegradable, long-acting subcutaneous pellet of naltrexone being developed in collaboration with the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), under RFA DA-19-002, “Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional)”. The Company had a previous pre-IND meeting with the FDA, at which time the FDA deemed the potentially shortened 505(b)(2) pathway acceptable, as well the opportunity to seek eventual dual indication on the product for OUD and Alcohol Use Disorder (AUD). According to data provided by the Centers for Disease Control and Prevention (CDC), over 81,000 drug overdose deaths occurred in the U.S. between June 2019 and May 2020. This data represents the most overdose deaths ever recorded in a 12-month period and experts attribute this increase, at least in part, to the COVID-19 pandemic. Tillkännagivande • Feb 27
BioCorRx Inc. announced that it has received $2.25 million in funding On February 26, 2021, BioCorRx Inc. (OTCPK:BICX) closed the transaction. The company issued 562,500 common shares for $1,125,000 to Joseph Galligan in its second and final tranche. Tillkännagivande • Feb 24
BioCorRx Inc. Appoints Joseph J. Galligan as Member of the Board, Effective February 17, 2021 On February 16, 2021, the Board of Directors of BioCorRx Inc. appointed Mr. Joseph J. Galligan as a member of the Board, effective February 17, 2021. Mr. Galligan had served as senior advisor to the Company since April 2019. He was formerly an Executive Vice President and Portfolio Manager at DoubleLine Capital LP.